LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Human natural regulatory CD4(+) T cells comprise 5-10% of peripheral CD4(+)T cells. They constitutively express the IL-2Ralpha-chain (CD25) and the nuclear transcription Foxp3. These cells are heterogeneous and contain discrete subsets with distinct phenotypes and functions. Studies in mice report that LAG-3 has a complex role in T cell homeostasis and is expressed in CD4(+)CD25(+) T regulatory cells. In this study, we explored the expression of LAG-3 in human CD4(+) T cells and found that LAG-3 identifies a discrete subset of CD4(+)CD25(high)Foxp3(+) T cells. This CD4(+)CD25(high)Foxp3(+)LAG-3(+) population is preferentially expanded in the PBMCs of patients with cancer, in lymphocytes of tumor-invaded lymph nodes and in lymphocytes infiltrating visceral metastasis. Ex vivo analysis showed that CD4(+)CD25(high)Foxp3(+)LAG-3(+) T cells are functionally active cells that release the immunosuppressive cytokines IL-10 and TGF-beta1, but not IL-2. An in vitro suppression assay using CD4(+)CD25(high)LAG-3(+) T cells sorted from in vitro expanded CD4(+)CD25(high) regulatory T cells showed that this subset of cells is endowed with potent suppressor activity that requires cell-to-cell contact. Our data show that LAG-3 defines an active CD4(+)CD25(high)Foxp3(+) regulatory T cell subset whose frequency is enhanced in the PBMCs of patients with cancer and is expanded at tumor sites.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, LAG3 can positively induce Treg cell activation and stimulate its immunosuppressive function [325, 326].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [326]
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“Moreover, although data remain controversial and depend on the type of tumor studied (21), a higher accumulation of Treg cells is often associated with advanced disease stages and is inversely correlated with favorable prognosis and overall survival (22, 23).”
BackgroundCD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606 · cited 1×
“This same set of markers, together with a low expression level of CD127 (6, 7), also identifies human natural Treg cells.”
BackgroundMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
CD4+CD25high Regulatory Cells in Human Peripheral Blood
Baecher-Allan, C., Brown, J. A., Freeman, G. J., & Hafler, D. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1245 · Cited by 1,859
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512 · cited 1×
“This same set of markers, together with a low expression level of CD127 (6, 7), also identifies human natural Treg cells.”
BackgroundICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
Jonuleit, H., Schmitt, E., Stassen, M., Tuettenberg, A., Knop, J., & Enk, A. H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1285 · Cited by 1,255 · cited 1×
“Natural Treg cells, upon TCR engagement (15, 16), exert their immunosuppressive functions in a contact-dependent fashion.”
BackgroundInterleukin‐10‐secreting type 1 regulatory T cells in rodents and humans
Grazia Roncarolo, M., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., & Levings, M. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00420.x · Cited by 1,173 · cited 1×
“Two subsets of induced Treg cells have been described and are shown to also exist in humans: Tr1 cells, which secrete high levels of IL-10 and arise from CD4 T cells upon encountering Ags in a tolerogenic environment (1), and Th3 cells, which are induced by oral Ag administration and secrete high levels of TGF-b1 (2).”
BackgroundDieckmann, D., Plottner, H., Berchtold, S., Berger, T., & Schuler, G. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1303 · Cited by 1,139
Levings, M. K., Sangregorio, R., & Roncarolo, M.-G. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1295 · Cited by 967
LAG-3, a novel lymphocyte activation gene closely related to CD4.
Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., & Hercend, T. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1393 · Cited by 925 · cited 1×
“Like ICOS, LAG-3 becomes expressed by T cells as a consequence of a TCR-mediated activation (45, 46).”
BackgroundInduction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells
Weiner, H. L. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820117.x · Cited by 846 · cited 13×
“It has been shown, for example, that Treg-derived IL-10 was mainly necessary for limitation of inflammation in the colon, lung, and skin (42), whereas recent data indicate that, at tumor sites, suppression is also due to the action of a subset of CD4+CD25+ Foxp3+ T cells that release IL-10 and TGF-b1 (37, 43).”
BackgroundInfluentialHiraoka, N., Onozato, K., Kosuge, T., & Hirohashi, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0369 · Cited by 831 · cited 1×
“Moreover, although data remain controversial and depend on the type of tumor studied (21), a higher accumulation of Treg cells is often associated with advanced disease stages and is inversely correlated with favorable prognosis and overall survival (22, 23).”
BackgroundRoncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S., & Levings, M. K. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820105.x · Cited by 814
Beyer, M., & Schultze, J. L. (2006) · Blood · doi:10.1182/blood-2006-02-002774 · Cited by 732 · cited 1×
“Moreover, although data remain controversial and depend on the type of tumor studied (21), a higher accumulation of Treg cells is often associated with advanced disease stages and is inversely correlated with favorable prognosis and overall survival (22, 23).”
BackgroundGrosso, J. F., Kelleher, C. C., Harris, T. J., Maris, C. H., Hipkiss, E. L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 547
Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and Periphery
Ito, T., Hanabuchi, S., Wang, Y.-H., Park, W. R., Arima, K., Bover, L., Qin, F. X.-F., Gilliet, M., & Liu, Y.-J. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.018 · Cited by 539 · cited 7×
“Like ICOS, LAG-3 becomes expressed by T cells as a consequence of a TCR-mediated activation (45, 46).”
BackgroundInfluentialStrauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J. T., & Whiteside, T. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0472 · Cited by 453
Human anergic/suppressive CD4+CD25+ T cells: a highly differentiated and apoptosis-prone population
Taams, L. S., Smith, J., Rustin, M. H., Salmon, M., Poulter, L. W., & Akbar, A. N. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200104)31:4<1122::aid-immu1122>3.0.co;2-p · Cited by 436
The Role of IL-10 and TGF-β in the Differentiation and Effector Function of T Regulatory Cells
Levings, M. K., Bacchetta, R., Schulz, U., & Roncarolo, M. G. (2002) · International Archives of Allergy and Immunology · doi:10.1159/000067596 · Cited by 422
MHC Class II Expression Identifies Functionally Distinct Human Regulatory T Cells
Baecher-Allan, C., Wolf, E., & Hafler, D. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4622 · Cited by 421
Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans
Morgan, M. E., van Bilsen, J. H. M., Bakker, A. M., Heemskerk, B., Schilham, M. W., Hartgers, F. C., Elferink, B. G., van der Zanden, L., de Vries, R. R. P., Huizinga, T. W. J., et al. (2005) · Human Immunology · doi:10.1016/j.humimm.2004.05.016 · Cited by 418 · cited 1×
“For example, studies have reported that TCRmediated activation of CD4CD25(2) T cells induces the transient expression of Foxp3 without conferring suppressive activity (8, 9).”
BackgroundHuman CD4+CD25+ regulatory T cells
Baecher-Allan, C. (2004) · Seminars in Immunology · doi:10.1016/j.smim.2003.12.005 · Cited by 385 · cited 1×
“Natural Treg cells, upon TCR engagement (15, 16), exert their immunosuppressive functions in a contact-dependent fashion.”
BackgroundNiyonsaba, F., Someya, A., Hirata, M., Ogawa, H., & Nagaoka, I. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200104)31:4<1066::aid-immu1066>3.0.co;2-# · Cited by 347
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)
Workman, C. J., & Vignali, D. A. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.688 · Cited by 332 · cited 1×
“LAG-3 has been recently described in mice as a novel Tregassociated marker that is directly involved in the control of T cell expansion and homeostasis (25, 26).”
BackgroundWang, H. Y., & Wang, R.-F. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.02.004 · Cited by 325
A peripheral circulating compartment of natural naive CD4 Tregs
Valmori, D., Merlo, A., Souleimanian, N. E., Hesdorffer, C. S., & Ayyoub, M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23963 · Cited by 319
Kono, K., Kawaida, H., Takahashi, A., Sugai, H., Mimura, K., Miyagawa, N., Omata, H., & Fujii, H. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0092-8 · Cited by 288 · cited 1×
“Human natural Treg cells constitutively express a high level of CD25 (15, 31–34) and the nuclear transcription factor Foxp3 (10, 35, 36).”
BackgroundImmunoregulatory T cells in tumor immunity
Terabe, M., & Berzofsky, J. A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.010 · Cited by 264
Regulatory T cells and treatment of cancer
Curiel, T. J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.04.008 · Cited by 262
Gandhi, M. K., Lambley, E., Duraiswamy, J., Dua, U., Smith, C., Elliott, S., Gill, D., Marlton, P., Seymour, J., & Khanna, R. (2006) · Blood · doi:10.1182/blood-2006-04-015164 · Cited by 255
The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery
Akbar, A. N., Vukmanovic-Stejic, M., Taams, L. S., & Macallan, D. C. (2007) · Nature Reviews Immunology · doi:10.1038/nri2037 · Cited by 216
Maçon‐Lemaître, L., & Triebel, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02145.x · Cited by 192
Ling, K. L., Pratap, S., Bates, G. J., Singh, B., Mortensen, N. J. M., George, B. D., Warren, B. F., Piris, J., Roncador, G., Fox, S. B., et al. (2007) · PubMed · Cited by 191
Joosten, S. A., van Meijgaarden, K. E., Savage, N. D. L., de Boer, T., Triebel, F., van der Wal, A., de Heer, E., Klein, M. R., Geluk, A., & Ottenhoff, T. H. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702257104 · Cited by 185
FOXP3: Not just for regulatory T cells anymore
Ziegler, S. F. (2007) · European Journal of Immunology · doi:10.1002/eji.200636929 · Cited by 170
Strauss, L., Bergmann, C., Szczepanski, M. J., Lang, S., Kirkwood, J. M., & Whiteside, T. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.2967 · Cited by 165
Ahmadzadeh, M., Felipe-Silva, A., Heemskerk, B., Powell, D. J., Wunderlich, J. R., Merino, M. J., & Rosenberg, S. A. (2008) · Blood · doi:10.1182/blood-2008-06-163048 · Cited by 141 · cited 13×
“It has been shown, for example, that Treg-derived IL-10 was mainly necessary for limitation of inflammation in the colon, lung, and skin (42), whereas recent data indicate that, at tumor sites, suppression is also due to the action of a subset of CD4CD25 Foxp3 T cells that release IL-10 and TGF-b1 (37, 43).”
BackgroundInfluentialCD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens.
Javia, L. R., & Rosenberg, S. A. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200301000-00009 · Cited by 135 · cited 1×
“Human natural Treg cells constitutively express a high level of CD25 (15, 31–34) and the nuclear transcription factor Foxp3 (10, 35, 36).”
BackgroundVukmanovic-Stejic, M., Agius, E., Booth, N., Dunne, P. J., Lacy, K. E., Reed, J. R., Sobande, T. O., Kissane, S., Salmon, M., Rustin, M. H., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35834 · Cited by 131
In vivo sites and cellular mechanisms of T reg cell–mediated suppression
Rudensky, A. Y., & Campbell, D. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060214 · Cited by 116 · cited 1×
“It is yet to be determined in vivo whether multifunctional Treg cells simultaneously use all of these mechanisms to suppress and restrain the immune response (41).”
BackgroundCasati, C., Dalerba, P. D., Rivoltini, L., Gallino, G., Deho, P., Rini, F., Belli, F., Mezzanzanica, D., Costa, A., Andreola, S. A., et al. (2003) · PubMed · Cited by 106
Tumor-specific regulatory T cells in cancer patients
Piersma, S. J., Welters, M. J. P., & van der Burg, S. H. (2008) · Human Immunology · doi:10.1016/j.humimm.2008.02.005 · Cited by 96 · cited 1×
“It has been clearly demonstrated that in most human solid tumors as well as hematologic malignancies, Ag-specific Treg cells actively suppress the proliferation of CD4CD25(2) and CD8 effector T cells, thereby limiting the immune response against cancer and contributing to tumor growth (24).”
BackgroundMantoux Test as a model for a secondary immune response in humans
Vukmanovic‐Stejic, M., Reed, J. R., Lacy, K. E., Rustin, M. H. A., & Akbar, A. N. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.08.002 · Cited by 92
Bayry, J., Triebel, F., Kaveri, S. V., & Tough, D. F. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4184 · Cited by 91
Thornton, A. M. (2005) · Current Biology · doi:10.1016/j.cub.2005.07.048 · Cited by 91
Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs
Tosello, V., Odunsi, K. O., Souleimanian, N. E., Lele, S., Shrikant, P. A., Old, L. J., Valmori, D., & Ayyoub, M. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.11.008 · Cited by 58
Cited by
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
“Lag-3+FoxP3+ Treg cells have been shown to be expanded in the PBMC, tumor-infiltrated lymph node, and tumor tissue of both melanoma and colorectal cancer patients (Camisaschi et al., 2010).”
BackgroundRegulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue, Y., & Nishikawa, H. (2019) · Cancer Science · doi:10.1111/cas.14069 · Cited by 1,041
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
LAG 3 (CD 223) as a cancer immunotherapy target
Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 956
“These LAG3+ Tregs display a terminal-effector (CD45RA+CCR7–) phenotype, and proliferate less than their LAG3-negative counterparts (83).”
BackgroundFibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Wang, J., Sanmamed, M. F., Datar, I., Su, T. T., Ji, L., Sun, J., Chen, L., Chen, Y., Zhu, G., Yin, W., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.010 · Cited by 871
Metadata
- Authors
- Camisaschi, C., Casati, C., Rini, F., Perego, M., De Filippo, A., Triebel, F., Parmiani, G., Belli, F., Rivoltini, L., & Castelli, C.
- Affiliations
- Unit of Immunotherapy of Human Tumors
- Immutep S.A., Faculté de Pharmacie , Chatenay-Malabry,
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Corresponding author
- Camisaschi, Chiara
- Casati, Chiara
- Rini, Francesca
- Perego, Michela
- Parmiani, Giorgio
- Rivoltini, Licia
- Castelli, Chiara
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-06-01
- Volume
- 184
- Issue
- 11
- Pages
- 6545-6551
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2147968481
- Cited by
- 350
- References
- 49
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 30 · 2023: 21 · 2022: 46 · 2021: 36 · 2020: 35 · 2019: 29 · 2018: 22 · 2017: 16 · 2016: 17 · 2015: 10 · 2014: 14 · 2013: 9 · 2012: 17
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- LAG-3, regulatory T cells, Foxp3, CD4+CD25high T cells, tumor-infiltrating lymphocytes, metastasis, immunosuppression, IL-10, TGF-β1, suppressor activity, cell-cell contact, tumor immunology, T cell subsets
- MeSH terms
- Lymphocyte Activation Gene 3 Protein, Cell Separation, Flow Cytometry, Humans, Lymphocyte Activation, Neoplasms, Antigens, CD, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Regulatory, Forkhead Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.